Peter Diamandis launches NeoGenesis Capital to back Colossal Biosciences spinouts in programmable biology
PeterDiamandis · x · 2026-10-15
Peter Diamandis announced NeoGenesis Capital, co-founded with Yianni Psaltis, to invest in Colossal Biosciences and spinout companies built on its platform across food, environment and more. The fund bets on the intersection of superintelligence and synthetic biology, with Oliver Trevena joining as Head of Culture.
More from Venture
- Tessara opens up: specialist AI agents that investigate your stock theses — tengyanAI · 2026-10-15
- a16z gutted its 34-person talent team, signaling tougher times ahead — SumitGup · 2026-10-15
- Thrive Capital partner: if you're AGI-pilled, you should be long healthcare — HealthcareAIGuy · 2026-10-15
- This 17-year bull market is up 1,073% — I/O Fund expects a correction first — Beth_Kindig · 2026-10-15
- Micron has returned 1,230% in three years, beating Nvidia, AMD and Broadcom 3-4x — Beth_Kindig · 2026-10-15
- Apple closes above $5 trillion market cap, second company in history to hit the mark — Polymarket · 2026-10-15